Jasper Therapeutics acquires Kira Pharmaceuticals; issues ~9.8M shares and raises $132M PIPE

Jasper Therapeutics, Inc.

Jasper issued ~5.2M common shares and ~4.6M convertible preferred shares to Kira shareholders; Kira holders own ~88.73% of pro forma common pre-PIPE.
Concurrent $132M PIPE from sale of ~4.7M preferred shares (convertible into 61 common each) to new investors; closing expected July 20, 2026.
Pre-merger Jasper shareholders receive one CVR per share entitling to pro rata share of $30M if FDA issues Priority Review Voucher for briquilimab by Dec 31, 2028.
Kira subsidiary entered Mirador License Agreement for anti-C5a assets; $12M upfront, up to $458.5M milestones, low-to-mid single-digit royalties.
Board changes: Vishal Kapoor and Scott Brun resigned; Patrick Crutcher appointed director; Matthew Ros appointed COO.

item 1.01 item 5.03 item 2.01 item 3.02 item 5.02 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.